Mye-EUNITER
 
Useful info
Links to related networks
Handy links
Related links

About us

This Action forms a network of researchers and clinicians which aims to establish a gold standard of common protocols and harmonizing guidelines for the analysis and clinical monitoring of MRCs. There is also a deficit in the translation of findings from animal models to humans, and Mye-EUNITER will build an analytical mouse-monkey-man correlation line. Standardized and validated tools for MRC analysis will aid the development of cellular biomarkers of disease and guide the design of novel therapies to manipulate the functions of MRCs.

Keywords:

Development of standardized analysis tools for MRCs; comparative analysis of MRCs in cancer, infectious and inflammatory diseases in murine, simian, and human models; therapeutic targeting of MRCs; pan-European network of biomedical PhD schools; translational immunology.

Why Mye-EUNITER?

Myeloid cells with regulatory function (e.g. myeloid suppressor cells, regulatory macrophages, or tolerogenic DC) have been shown to be detrimental in infections, inflammation and cancer, but have become a promising therapeutic tool to treat autoimmune diseases, severe allergies, or to improve transplantation outcomes. A variety of MRC subtypes in the human and mouse immune system have been identified in the last few years, but the lack of consensus on markers as well as protocols and methods to detect them makes it difficult to study and compare these cells in different diseases and experimental models. Although research on MRC subtypes is well-funded by individual grants throughout the European Union, the above mentioned obstacles hamper the rapid development of effective therapies, which either target or utilize immunoregulation through MRCs. This Action will harmonize and coordinate dispersed individual and national research activities in the field on a European level. This Action will enable researchers to form a network of experts in basic, translational and clinical research in order to promote the diagnostic and clinical application of MRCs in socio-economically important diseases. This being said, Mye-EUNITER will address both European economic/societal needs and will advance scientific knowledge in the field. MRCs are involved in the pathobiology of infectious and malignant diseases, which cause a major socio-economic burden to the European health system. Standardized tools developed by this Action will improve the diagnosis and the development of therapeutic options for these diseases. The latter part will be performed in joint efforts with biotech industry whenever feasible. At the same time, these tools and protocols will enhance the scientific knowledge in the field. This will be achieved by the exchange of technologies, analytical tools, obtained data, and researchers at several levels:

  • Data exchange between researchers working on different subsets of MRCs will increase scientific knowledge on the cell biology of these cells. 
  • Exchange of knowledge, data and tools between researchers working on rodents, non-human primates and humans will promote the development of new pre-clinical models for MRC analysis.
  • Exchange between basic researchers and clinicians in this Action will facilitate the prospect of the clinical application of protocols and tools used for diagnosis and monitoring of disease progression/treatment.
  • Exchange of know-how with industrial partners in this Action will improve the development of diagnostics and therapeutics.